GlassScriptPhysician profile
Sanford J Kim
NPI 1891782454
$1,965.55
in general payments reported to CMS, 2019-2025
24 companies · $980 in 2025
The $980 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.27 · 2024: $965 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.32 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $481.02 | 2024-2025 | |
| Novo Nordisk INC | $188.73 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $181.34 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $140.96 | 2024-2025 | |
| Exact Sciences Corporation | $123.50 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $120.08 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Astellas Pharma US INC | $109.29 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $80.82 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.35 | 2024-2025 | Jardiance, Jascayd, Synjardy |
| Xeris Pharmaceuticals, INC. | $60.22 | 2025 | Gvoke Hypopen |
| Lilly USA, LLC | $55.92 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $51.87 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $47.88 | 2024-2025 | Spravato |
| Corcept Therapeutics | $36.16 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $33.91 | 2024 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $32.72 | 2024 | (Ck7) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2024 | |
| Merck Sharp & Dohme LLC | $22.60 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $22.45 | 2024 | Eliquis |
| Daiichi Sankyo INC. | $21.27 | 2019 | |
| Esperion Therapeutics, INC. | $17.47 | 2025 | Nexletol |
| Seqirus USA INC | $16.78 | 2024 | Flucelvax, Fluad |
| Sumitomo Pharma America, INC. | $16.62 | 2025 | Gemtesa |
| Boston Scientific Corporation | $13.60 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanford Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.